63% of millennials and 61% of Gen Zers feel more connected to health brands since starting GLP-1s, per a January Dentsu report.
The trend: Most healthcare and pharma marketers plan to increase their CTV/over-the-top (OTT) spending in the next year, according to Nielsen’s Global Annual Marketing Survey. Our take: CTV’s gain of healthcare and pharma ad dollars isn’t necessarily linear TV’s loss. Campaign strategies for linear should focus on brand awareness, while CTV allows drug ads to be highly targeted.
The news: Novo Nordisk is partnering with WeightWatchers to offer discounted Wegovy to cash-pay customers. Our take: WeightWatchers is recognizing that diet culture is being replaced by weight loss medications accessible via virtual care. To stand out from other Novo’s other telehealth partners, WeightWatchers should lean into marketing that positions the company as a pioneer weight loss brand that’s now meeting consumer demand for GLP-1s.
The news: Consumers who are more familiar with AI are also more likely to mistrust an AI-assisted diagnosis from their doctor, per a recently published Journal of Medical Internet Research survey. Our take: Physicians and healthcare marketers can’t assume people who are familiar with AI will be more comfortable with AI uses in healthcare. Marketers need to talk about AI as a tool with many positive effects like freeing doctors for longer personal interactions and resulting in fewer mistakes.
The upshot: The first meeting of a new and controversial CDC vaccine advisory panel signaled its intent to focus on childhood immunizations. The panel may change childhood vaccination approvals and scheduling. Our take: Pharma vaccine makers can’t stay quiet for much longer and can take a page from the medical associations by messaging to consumers and parents that they stand by their products.
The trend: US consumers trust the pharma companies that advertise the prescription drugs they’re taking. Our take: Pharma companies can take heart in knowing the people who take their drugs trust them and their advertising. But it’s also an opportunity for precise data and media targeting to reach new consumers who would be interested in their medication—undiagnosed people or competitors’ patients—and receptive to learning about them.
The news: During a Congressional subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. laid out his vision for all Americans to use a wearable with health-tracking capabilities within four years. Our take: Marketers should use Kennedy’s enthusiasm for wearables to their advantage. They should get out in front of the government’s ad campaign by developing their own promotions that inform consumers of wearables’ evolved health-tracking features beyond just counting calories and steps. They could target people who aren’t as familiar or have never used a health wearable due to price concerns or lack of tech-savviness.
The trend: Over three-quarters of US hospitals now task pharmacists with patient care responsibilities, according to a recently published survey from the American Society of Health System Pharmacists. Our take: Struggling retail pharmacies should also entrust pharmacists to play a bigger role in patient care, especially as some drugstores pivot to health-focused store formats.
The news: A majority of GLP-1 weight loss drug consumers are now staying on the medications for more than a year, per an annual Prime Therapeutics analysis. The Prime study includes 5,780 people via healthcare claims over three years; the mean age was 47 and 80% were women. The final word: Adherence rates longer than a year validates the idea that prescription weight loss GLP-1s, and newer drugs on the way, are here to stay as chronic disease treatments. It shifts typical weight loss marketing from cyclical—keep your New Year’s resolution or lose weight for your wedding—to medical and consistent.
The news: Novo Nordisk is terminating its short-lived partnership with Hims & Hers. The drugmaker is accusing Hims of illegally selling knockoff versions of Wegovy, while deceptively marketing its compounded GLP-1 products. Our take: Hims will likely regret its refusal to cooperate with Novo and Eli Lilly, who have taken control of the D2C weight loss drug market.
The news: Around 50 health plans— including large players UnitedHealthcare, CVS Health, Cigna, and Elevance Health—are pledging to simplify the prior authorization process. Our take: But their commitments don’t come with mandates or enforcement—meaning insurers can still get away with tactics that boost their profits over paying for expensive medical care.
The news: BetterHelp inked a deal with three WNBA teams to market and raise awareness of mental health services. Our take: Marketing healthcare products and services by making brand connections to aspirational healthiness via sports is a savvy strategic play for BetterHelp. The company’s lean into women’s sports, and especially tapping the surging popularity of the WNBA with relatable personal stories on Instagram, carves out a niche.
The news: The Trump administration is mulling new policies to make pharma advertising more difficult, per a Bloomberg report. Our take: RFK previously acknowledged the First Amendment hurdles in an outright pharma ad ban. But if he takes an alternate path with new D2C ad regulations, it’s a win for the industry. Pharma companies can budget for extra media costs of additional TV time and the loss of ad tax deductions, but they get to keep D2C advertising.
The news: Gilead’s long-lasting injection for HIV prevention received FDA approval, but the breakthrough drug comes with a high price tag ($28,218 annual list price). The takeaway: Another breakthrough drug with a high price tag adds fuel to the long-held idea that pharma puts profits over patients. Drugmakers need to offer and advertise practical solutions, such as direct financial help, and will need to fund more nonprofit programs to change perceptions.
The trend: Healthcare advertising motivates consumers to go online to do more research, or talk to a medical professional—but the majority of people have privacy concerns about personalized ads. Our take: Healthcare marketers are eager to use AI and targeting technology to make one-to-one connections with consumers. And it’s true that personalized ads can be more useful for people. However, marketers need to use transparent labeling, use conspicuous ad tags on social media, and preface targeted emails with explanations about why they’re being sent.
The trend: Younger generations continue to prioritize wellness more than older consumers and are purchasing products across a range of health and well-being categories. Our take: Sharing practical tips and advice is helpful, but brands and marketers can further stand out on social platforms by replying to users’ comments and questions within a post. Building partnerships with wellness influencers is essential, and it’s important to find creators who have real-life experiences that are relatable to the targeted audience.
The news: Oura is partnering with Maven Clinic to integrate smart ring data with providers’ care and treatment plans. Our take: We think it will take a while for providers to incorporate device data into the decisions they make for patients, which are typically based on clinical research studies and medical literature. Oura shouldn’t bet too heavily on securing doctors’ trust, and instead home in on the recent advancements it’s making on using AI to drive a better consumer experience.
The news: Prescription drug approval timelines will shrink under an FDA pilot program that will reduce the approval timelines from a typical 10 months to just 1 to 2 months. Our take: Speedier reviews and new AI programs for drug developers are good ideas, but pharma companies should remember the COVID-19 vaccines speed-to-market backlash and weigh the time benefit against whether their drugs will gain trust with physicians and patients.
The trend: Women see and hear more health-related information than men, especially when it comes to weight loss drugs and anti-aging treatments. Our take: Pharma and healthcare marketers need to more effectively reach women. Instead of marketing to all women, market to mindsets like self-care via social media influencers’ tips and advice, or motivations like caregiving and prevention by tapping into mammogram screening advocacy and resources that support overburdened women who care for loved ones.
The data: Around 2 in 5 employers and health plans will never consider covering GLP-1 drugs for obesity, according to a June 2025 report from Pharmaceutical Strategies Group. Our take: We don’t think a lack of insurance coverage for GLP-1s will lead to a market slowdown. Less generous insurance coverage of the drugs will force companies operating in the competitive cash-pay GLP-1 space to continue offering temporary discounts or lower their prices altogether.